ConductScience.org, home

Comparison · NCT04335123-d684b53d

Open Label Losartan vs External Controls: Number of Participants With Intolerance to High Dose (50mg) Losartan After Tolerating 25mg

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Open Label Losartan vs External Controls: Number of Participants With Intolerance to High Dose (50mg) Losartan After Tolerating 25mg. Trial comparisons, record NCT04335123-d684b53d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04335123-d684b53d

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.06670.01850.213wilson
Risk in group 2000.0771wilson
Risk difference, group 1 minus group 20.0667-0.02420.213newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on Open Label Losartan than on External Controls15from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Open Label Losartan
34 patients with COVID-19 and respiratory failure participated in the study and were placed on losartan 25 mg once daily on study day 0. Losartan dose was increased to 50 mg once daily on study day 3. Participants continued losartan until they experienced resolution of respiratory failure (normal oxygen levels on room air), were discharged from the hospital, met stoppage criteria or completed 14 days of therapy.~Losartan: 25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion
230OG000
Group 2External Controls46 external controls matched to losartan participants upon baseline characteristics.046OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Intolerance to High Dose (50mg) Losartan After Tolerating 25mg
Description
Number of participants with intolerance to high dose (50mg) losartan after tolerating 25mg
Time frame
14 days of losartan treatment
Population

Source ClinicalTrials.gov

Trial

Title
Study of Open Label Losartan in COVID-19
NCT number
NCT04335123
Phases
PHASE1
Conditions
COVID-19
Interventions
Losartan
Lead sponsor
University of Kansas Medical Center
Results first posted
2024-08-02

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04335123-d684b53d